Anheuser-Busch InBev SA/NV vs AbbVie Inc.: Strategic Comparison

This in-depth comparison examines Anheuser-Busch InBev SA/NV and AbbVie Inc. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Anheuser-Busch InBev SA/NV on its own, evaluating AbbVie Inc., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Anheuser-Busch InBev SA/NV and AbbVie Inc. is widest.

On the headline numbers, Anheuser-Busch InBev SA/NV reports annual revenue of $59.3B against $61.2B for AbbVie Inc., while their respective market capitalizations stand at $158.7B and $451.5B. Anheuser-Busch InBev SA/NV is headquartered in Belgium and AbbVie Inc. operates from United States, and those different home markets shape how each company competes.

Anheuser-Busch InBev SA/NV: AB InBev is a public Belgian brewer with global scale, major beer brands, and a digital route-to-market strategy. The company reported FY2025 net revenue of $59.32 billion and remains one of the most important consumer staples businesses to watch because it sits at the intersection of alcohol consumption, premiumization, emerging markets, direct commerce, and M&A.

AbbVie Inc.: AbbVie began as the separated pharmaceutical arm of Abbott Laboratories and became one of the world's largest biopharma companies by using Humira cash flow to build a broader portfolio. The company now presents itself as a diversified specialty-medicine platform rather than a single-product story.

Anheuser-Busch InBev SA/NV and AbbVie Inc. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Anheuser-Busch InBev SA/NV and AbbVie Inc..

Anheuser-Busch InBev SA/NV business model: AB InBev makes money by selling beer and beverages through wholesalers, retailers, bars, restaurants, stadiums, supermarkets, convenience stores, and digital platforms. The model depends on volume, revenue per hectoliter, premium mix, procurement scale, efficient breweries, and marketing around global brands such as Budweiser, Corona, Stella Artois, and Michelob Ultra. BEES strengthens the route to market by digitizing retailer ordering and capturing demand data, while direct-to-consumer platforms and Beyond Beer products add growth outside traditional lager occasions.

AbbVie Inc. business model: AbbVie earns revenue from patented and specialty medicines sold globally through healthcare systems, insurers, distributors, specialists, hospitals, and aesthetics providers. Immunology is the largest segment, supported by neuroscience, oncology, aesthetics, eye care, and other therapeutics.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Anheuser-Busch InBev SA/NV stack up against those of AbbVie Inc..

Anheuser-Busch InBev SA/NV competitive advantage: AB InBev's moat comes from scale. Few competitors can match its global brand portfolio, procurement leverage, brewing capacity, distribution reach, marketing budget, and retailer relationships. BEES adds a digital layer to that moat by making ordering easier for millions of customers and giving AB InBev better data on demand, assortment, pricing, and route planning.

AbbVie Inc. competitive advantage: AbbVie's advantage comes from deep immunology scale, specialist sales relationships, strong cash flow, global clinical and regulatory capabilities, and a portfolio led by Skyrizi, Rinvoq, Botox, Vraylar, Imbruvica, Venclexta, and Elahere.

Future prospects matter as much as current results. The growth strategies below explain how Anheuser-Busch InBev SA/NV and AbbVie Inc. each plan to expand from here.

Anheuser-Busch InBev SA/NV growth strategy: AB InBev's growth strategy centers on premiumization, beer category expansion, no-alcohol beer, Beyond Beer, BEES, direct-to-consumer delivery, and disciplined capital allocation. The company is using megabrands such as Corona, Stella Artois, Budweiser, and Michelob Ultra to raise revenue per hectoliter while using BEES to deepen retailer relationships and improve execution in both developed and emerging markets.

AbbVie Inc. growth strategy: AbbVie's growth strategy is to expand indications for Skyrizi and Rinvoq, defend Botox and aesthetics, invest in neuroscience and oncology, use targeted acquisitions to add late-stage assets, and maintain disciplined cash generation after Humira's decline.

A closer look at the financial trajectory of Anheuser-Busch InBev SA/NV and AbbVie Inc. rounds out the comparison.

Anheuser-Busch InBev SA/NV: FY2025 showed a stable but mixed picture. Reported net revenue was $59.32 billion, impacted by currency translation, while organic revenue grew 2.0% and revenue per hectoliter rose 4.4%. Normalized EBITDA reached $21.2 billion, underlying profit reached $7.41 billion, and free cash flow was $11.3 billion. The key investor question is whether price, premiumization, BEES, and cost discipline can keep EBITDA growing while volumes remain uneven across markets.

AbbVie Inc.: AbbVie generated $61.160 billion in FY2025 net revenue, up 8.6% on a reported basis, with immunology contributing $30.406 billion. Q1 2026 revenue reached $15.002 billion, showing continued growth after the Humira patent cliff as Skyrizi and Rinvoq scaled.